JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

PerkinElmer Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

0

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

Pagrindiniai rodikliai

By Trading Economics

Pajamos

13M

55M

Pardavimai

56M

720M

P/E

Sektoriaus vid.

38.234

34.393

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.32

Pelno marža

7.569

Darbuotojai

11,000

EBITDA

-82M

91M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+30.75% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.32%

2.54%

Kitas uždarbis

2025-11-03

Kitas dividendų mokėjimo data

2025-11-07

Kita Ex Dividend data

2025-10-17

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-283M

10B

Ankstesnė atidarymo kaina

0

Ankstesnė uždarymo kaina

0

Naujienos nuotaikos

By Acuity

39%

61%

125 / 374 reitingas Healthcare

PerkinElmer Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-11 17:49; UTC

Pagrindinės rinkos jėgos

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025-08-11 17:18; UTC

Pagrindinės rinkos jėgos

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025-08-11 16:25; UTC

Uždarbis

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025-08-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025-08-11 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025-08-11 23:32; UTC

Rinkos pokalbiai

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025-08-11 23:02; UTC

Rinkos pokalbiai

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025-08-11 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement 2Q Rev $25.8M >EXOD

2025-08-11 20:14; UTC

Rinkos pokalbiai

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025-08-11 19:12; UTC

Rinkos pokalbiai

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025-08-11 18:56; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025-08-11 18:31; UTC

Rinkos pokalbiai

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025-08-11 17:43; UTC

Rinkos pokalbiai

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025-08-11 17:28; UTC

Rinkos pokalbiai

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025-08-11 17:16; UTC

Rinkos pokalbiai

Commodity Longs Fall to 11-Month Low -- Market Talk

2025-08-11 16:42; UTC

Įsigijimai, susijungimai, perėmimai

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025-08-11 16:27; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Says Sabadell Offer Remains in Effect

2025-08-11 16:26; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Announced TSB Sale on July 1

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Akcijų palyginimas

Kainos pokytis

PerkinElmer Inc Prognozė

Kainos tikslas

By TipRanks

30.75% į viršų

12 mėnesių prognozė

Vidutinis 113.54 USD  30.75%

Aukščiausias 135 USD

Žemiausias 100 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines PerkinElmer Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

8

Pirkti

5

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

125 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.